Why Risk CIN?

Of the 4.2 million diagnostic (angiograms) and therapeutic (angioplasties / stent placements) coronary procedures performed each year in the U.S., 1.3 million are performed on patients with chronic kidney disease (CKD) or those with diabetes or hypertension at risk for kidney impairment. Contrast induced nephropathy (CIN) occurs because the contrast media used to image the coronary arteries in these procedures can be toxic to the kidneys. While it can’t be predicted which patients will develop (CIN), the incident rate is 7.5% to 53.3 % in kidney risk populations depending on individual risk factors.

CIN not only leads to adverse clinical outcomes it is very expensive to treat. At its worse CIN requires acute dialysis at an average cost approaching $40,000.

On Track to Stop CIN
St. Paul-based Osprey Medical Inc. has a singular vision to pioneer patent-pending catheter technology to address the unmet clinical need to stop CIN. Backed by its seasoned management team and Series A equity financing, Osprey Medical is pursuing Series B financing and advancing FDA approval for the CINCOR™  system, a breakthrough technology to prevent CIN that is more cost effective than treating CIN, simple to use and easily adopted by interventional cardiologists.